↓ Skip to main content

NQO1-Mediated Tumor-Selective Lethality and Radiosensitization for Head and Neck Cancer

Overview of attention for article published in Molecular Cancer Therapeutics, July 2016
Altmetric Badge

About this Attention Score

  • In the top 25% of all research outputs scored by Altmetric
  • High Attention Score compared to outputs of the same age (81st percentile)
  • High Attention Score compared to outputs of the same age and source (81st percentile)

Mentioned by

news
1 news outlet
twitter
1 tweeter

Citations

dimensions_citation
37 Dimensions

Readers on

mendeley
35 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
NQO1-Mediated Tumor-Selective Lethality and Radiosensitization for Head and Neck Cancer
Published in
Molecular Cancer Therapeutics, July 2016
DOI 10.1158/1535-7163.mct-15-0765
Pubmed ID
Authors

Long-Shan Li, Srilakshmi Reddy, Zhen-Hua Lin, Shuangping Liu, Hyunsil Park, Stephen G. Chun, William G. Bornmann, Joel Thibodeaux, Jingsheng Yan, Gaurab Chakrabarti, Xian-Jin Xie, Baran D. Sumer, David A. Boothman, John S. Yordy

Abstract

Ionizing radiation (IR) is a key therapeutic regimen for many head and neck cancers (HNCs). However, the 5-year overall survival rate for locally-advanced HNCs is ~50% and better therapeutic efficacy is needed. NAD(P)H:quinone oxidoreductase 1 (NQO1) is over-expressed in many cancers, and β-lapachone (β-lap), an unique NQO1 bioactivatable drug, exploits this enzyme to release massive reactive oxygen species (ROS) levels that synergizes with IR to kill by programmed necrosis. β-Lap represents a novel therapeutic opportunity in HNC leading to tumor-selective lethality that will enhance the efficacy of ionizing radiation. Immunohistochemical staining and western blot assays were used to assess the expression levels of NQO1 in HNC cells and tumors. Forty-five percent of endogenous HNCs express elevated NQO1 levels. In addition, multiple HNC cell lines and tumors demonstrated elevated levels of NQO1 expression and activity and were tested for anticancer lethality and radiosensitization by β-lap using long-term survival assays. The combination of nontoxic β-lap doses and IR significantly enhanced NQO1-dependent tumor cell lethality, increased ROS, TUNEL positive cells, DNA damage, NAD+ and adenosine triphosphate (ATP) consumption, and resulted in significant antitumor efficacy and prolonged survival in two xenograft murine HNC models, demonstrating β-Lap radiosensitization of HNCs through a NQO1-dependent mechanism. This translational study offers a potential biomarker-driven strategy using NQO1 expression to select tumors susceptible to β-lap-induced radiosensitization.

Twitter Demographics

The data shown below were collected from the profile of 1 tweeter who shared this research output. Click here to find out more about how the information was compiled.

Mendeley readers

The data shown below were compiled from readership statistics for 35 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
United States 1 3%
Unknown 34 97%

Demographic breakdown

Readers by professional status Count As %
Student > Ph. D. Student 7 20%
Student > Bachelor 5 14%
Researcher 4 11%
Student > Master 4 11%
Student > Doctoral Student 2 6%
Other 5 14%
Unknown 8 23%
Readers by discipline Count As %
Medicine and Dentistry 10 29%
Biochemistry, Genetics and Molecular Biology 6 17%
Pharmacology, Toxicology and Pharmaceutical Science 2 6%
Agricultural and Biological Sciences 2 6%
Veterinary Science and Veterinary Medicine 1 3%
Other 3 9%
Unknown 11 31%

Attention Score in Context

This research output has an Altmetric Attention Score of 10. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 15 August 2022.
All research outputs
#3,063,323
of 22,032,472 outputs
Outputs from Molecular Cancer Therapeutics
#453
of 3,802 outputs
Outputs of similar age
#50,326
of 281,918 outputs
Outputs of similar age from Molecular Cancer Therapeutics
#13
of 76 outputs
Altmetric has tracked 22,032,472 research outputs across all sources so far. Compared to these this one has done well and is in the 85th percentile: it's in the top 25% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 3,802 research outputs from this source. They typically receive more attention than average, with a mean Attention Score of 8.0. This one has done well, scoring higher than 87% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 281,918 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 81% of its contemporaries.
We're also able to compare this research output to 76 others from the same source and published within six weeks on either side of this one. This one has done well, scoring higher than 81% of its contemporaries.